When Will Mounjaro Be Available on the NHS?

Which cohort is open right now, and who qualifies?

NICE recommended tirzepatide for NHS use in December 2024 (NICE technology appraisal TA1026), and NHS England began commissioning it through GP practices in June 2025. Because the medicine cannot be made available to everyone at once, access is being released in stages tied to clinical need.

The first cohort (active since June 2025) is limited to adults with a BMI of 40 or above who have four or more of the five qualifying conditions: type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea, and cardiovascular disease. That is a high bar. Many people who could benefit do not yet meet it.

The second cohort opened on 23 June 2026, extending eligibility to adults with a BMI of 35–39.9 who still have four or more of those same conditions. If your BMI falls in that range and you have multiple comorbidities, it is worth speaking to your GP now. For some ethnic backgrounds (including South Asian, Chinese, Middle Eastern, Black African and African-Caribbean) the BMI thresholds are 2.5 kg/m² lower throughout, in line with UK clinical guidance.

Even within an open cohort, access is not automatic. GP practices can opt in to the new prescribing arrangements under the 2026/27 QOF contract, but participation is voluntary. Your practice may not yet be commissioned to prescribe Mounjaro, regardless of whether you meet the criteria on paper. A quick call to your surgery to ask whether they are taking part can save a wasted appointment.

When does the rollout open further — and what comes next?

Two more phases are planned. From around March 2027, the criteria are expected to broaden to adults with a BMI of 40 or above with three qualifying conditions, rather than four. Further tranches beyond that have not been formally announced at the time of writing, but the trajectory is clearly towards wider access over time.

It is worth reading about the full timeline of NHS Mounjaro availability if you want to map out exactly where the goalposts are likely to move. The phasing exists partly to manage NHS capacity and partly because the wraparound support (dietary guidance, activity support, and clinical monitoring) that every NHS patient must receive alongside the medicine takes real resource to deliver. Meeting the BMI and condition criteria is necessary but not sufficient; patients also need to be enrolled in that structured support programme.

Scotland, Wales and Northern Ireland each commission healthcare separately. Criteria and timelines differ, so if you are outside England, NHS Inform Scotland's guidance is a useful starting point, and checking with your local health board is the most reliable route.

What if you do not yet meet the NHS criteria?

This is the question our prescribers hear most weeks. The honest answer is that a significant number of people who could clinically benefit from tirzepatide fall just outside the current NHS cohorts, their BMI is 38 rather than 40, or they have two conditions rather than four, or their GP practice has not yet opted into the scheme.

For those people, a private prescription through a GPhC-registered pharmacy is the legal alternative. The private eligibility criteria follow the licensed indications in the medicine's SmPC: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. That is a meaningfully broader group than the NHS currently reaches. The prescriber still assesses the full clinical picture (there is no shortcut) but the threshold is different.

If you are thinking about that route, it is sensible to read about what Mounjaro is and how it works before your consultation, so you can ask the right questions. Private treatment costs are also worth understanding clearly; our treatment overview page sets out exactly what is included in a single transparent price, with no hidden fees and no subscription.

Is Mounjaro on the NHS the same as getting it privately?

The medicine is identical, both routes dispense the same tirzepatide KwikPen, manufactured by Eli Lilly through the licensed UK supply chain. What differs is the clinical framework around it and the cost to you.

NHS patients receive Mounjaro as part of a multidisciplinary weight management programme; the prescription itself carries a standard prescription charge or is free if you hold an exemption. Private patients pay for the medicine, the prescription, and the clinical oversight, though a well-structured private service bundles all of those together. There is no waiting list and no cohort threshold to pass, but the prescriber still has clinical and legal obligations to meet before issuing any prescription.

One thing both routes share: the clinical review comes first. Mounjaro is a prescription-only medicine, and that classification exists for good reason. Anyone offering it without a formal assessment is not operating within the law. If you are wondering whether private access might suit you while you wait for NHS eligibility to catch up as the rollout broadens, a guided overview of how to access Mounjaro safely in the UK is a practical next step. And if you want to understand the GPs' role in the new NHS prescribing model, the detail on when GPs can prescribe Mounjaro explains how the QOF arrangements work in practice, including what the current stock situation means for both NHS and private patients.